| Bioactivity | ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC50 of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes[1]. |
| CAS | 1016427-72-7 |
| Formula | C20H16FN3O4S2 |
| Molar Mass | 445.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hasegawa S, et al. Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or p38α MAPK selectivity. Biochem Biophys Res Commun. 2024 Apr 16;704:149707. [2]. Kinoshita T, et al. Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay. Bioorg Med Chem Lett. 2016 Feb 1;26(3):955-958. |
ERK2/p38α MAPK-IN-1
CAS: 1016427-72-7 F: C20H16FN3O4S2 W: 445.49
ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC50
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.